![[Alpha Tau in PR Newswire] Alpha Tau announces receipt of radioactive license to allow production in main manufacturing floor at its Jerusalem site, amended radioactive license with increased capacity at Lawrence, MA site](https://blog.ourcrowd.com/wp-content/uploads/2017/09/PR_newswire.jpg "[Alpha Tau in PR Newswire] Alpha Tau announces receipt of radioactive license to allow production in main manufacturing floor at its Jerusalem site, amended radioactive license with increased capacity at Lawrence, MA site")
[ad_1]
JERUSALEM, June 16, 2022 /PRNewswire/ — Alpha Tau Medical Ltd. (Nasdaq: DRTS) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that the Israeli Ministry of Environmental Protection has granted the Company an active radioactive license for use and possession of Thorium-228 and Radium-224, radioactive materials which are utilized in the production of the Alpha DaRT sources, in the main manufacturing floor of the Company’s production facility in Jerusalem.
Read more here.
[ad_2]
![[Ravin AI in CTECH] “Once you dive in from your starting point, you suddenly realize there’s this whole world of opportunity.”](https://blog.ourcrowd.com/wp-content/uploads/2019/05/ctech-NEW.jpg "[Ravin AI in CTECH] “Once you dive in from your starting point, you suddenly realize there’s this whole world of opportunity.”")